Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
Davide MatinoAlfonso IorioArun KeepanasserilFederico GerminiAlexandre CaillaudManuel CarcaoJulia Hews-GirardEmma IsermanPaula D JamesAdrienne LeeChai W PhuaHaowei Linda SunJerome TeitelMan-Chiu PoonPublished in: Research and practice in thrombosis and haemostasis (2022)
Results from this first real-world study of N9-GP in patients with hemophilia B suggest optimal bleeding control with low factor consumption after switching to N9-GP, irrespective of the previous product.